Table 1.

Correlation between the mRNA levels of insulin‐like growth factor binding protein 5 (IGFBP5) and clinicopathologic factors

Clinicopathologic factors	Cases	x̄ ± s	t/F	P‐value
Breast sample
Normal breast	30	1.45E‐04 ± 1.83E‐04	–5.092	0.000
Breast cancer	108	1.08E‐02 ± 2.15E‐02
Tumor size (cm)
≤2	50	7.95E‐03 ± 1.59E‐02	0.970	0.382
2–5	50	1.38E‐02 ± 2.69E‐02
>5	8	8.37E‐03 ± 1.01E‐02
Lymph node status
Negative	52	4.65E‐03 ± 9.11E‐03	2.995	0.004
Positive	56	1.63E‐02 ± 2.75E‐02
Lymph node positive number
0	52	4.65E‐03 ± 9.11E‐03	3.811	0.012
1–3	22	2.00E‐02 ± 2.89E‐02
4–9	15	1.92E‐02 ± 3.29E‐02
≥10	19	9.71E‐03 ± 2.08E‐02
Clinical stage
I	15	1.24E‐02 ± 1.81E‐02	0.475	0.700
II	67	8.90E‐03 ± 1.97E‐02
III	22	1.50E‐02 ± 2.93E‐02
IV	4	1.04E‐02 ± 1.48E‐02
Nuclear grade †
I	12	8.91E‐03 ± 1.61E‐02	0.774	0.464
II	73	9.41E‐03 ± 1.92E‐02
III	23	1.56E‐02 ± 2.98E‐02
ER ‡
Positive	67	1.31E‐02 ± 2.63E‐02	2.209	0.030
Negative	37	5.61E‐03 ± 6.68E‐03
Missing	4
PR ‡
Positive	46	1.50E‐02 ± 2.84E‐02	1.835	0.071
Negative	58	6.71E‐03 ± 1.32E‐02
Missing	4
Her2 §
Positive	28	1.05E‐02 ± 2.15E‐02	0.345	0.731
Negative	55	9.03E‐03 ± 1.81E‐02
Missing	25
Relapse or distant metastasis
Negative	54	7.52E‐03 ± 1.22E‐02	0.938	0.359
Positive	19	1.33E‐02 ± 2.59E‐02
Less than 3 years follow up	35

^† Grade I nuclei indicates well‐differentiated breast cells that generally appear normal; Grade III shows poorly differentiated breast cells that do not appear normal; and Grade II has characteristics between Grade I and Grade III tumors with moderately differentiated breast cells.

^‡ Positive when more than 15% of the membrane showed staining by immunohistochemical staining.

^§ Positive when more than 10% of the nuclei showed staining by immunohistochemical staining.